The Alliance for Regenerative Medicine (ARM) has recently released its annual report. Notably, ARM states that 2019 was the second-best year in history for regenerative medicine financing. A whopping $9.8 billion US was raised globally. $7.8 million was raised for gene modified and cell therapy. Tissue engineering received $442 million. The report further specifies deals for significant sums as well as public offerings. The financing numbers are also broken down by type, such as venture capital, with comparison to 2018 and 2017 numbers. VC financing is up almost a billion dollars in 2019 over 2018. Financing numbers are also reviewed for the EU and Israel. The report also specifies that there are 1,066 clinical trials proceeding at the end of 2019. New approvals and expected approvals are also discussed.
Friday 6 March 2020
Alliance for Regenerative Medicine: 2019 is Second Best Year in History for Regenerative Medicine Financing
The Alliance for Regenerative Medicine (ARM) has recently released its annual report. Notably, ARM states that 2019 was the second-best year in history for regenerative medicine financing. A whopping $9.8 billion US was raised globally. $7.8 million was raised for gene modified and cell therapy. Tissue engineering received $442 million. The report further specifies deals for significant sums as well as public offerings. The financing numbers are also broken down by type, such as venture capital, with comparison to 2018 and 2017 numbers. VC financing is up almost a billion dollars in 2019 over 2018. Financing numbers are also reviewed for the EU and Israel. The report also specifies that there are 1,066 clinical trials proceeding at the end of 2019. New approvals and expected approvals are also discussed.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment